Diagnosis of prostate cancer: the implications and proper utilization of PSA and its variants; indications and use of MRI and biomarkers.

Le résumé fourni par la source

Prostate cancer screening remains highly controversial in medicine. The College of Family Physicians of Canada currently endorses positions that recommend against prostate-specific antigen (PSA) screening in men of all ages, while the Canadian Urological Association recommends shared and informed decision making for PSA screening in men 50-70 years old. Unfortunately, these opposing stances have left Family Physicians responsible for interpreting the appropriate course of action for their patients. Recent studies demonstrating an increase in incidence of metastatic prostate cancer have led to our support of the Canadian Urological Association recommendations. In an attempt to facilitate initial patient investigation, this article aims to outline current prostate cancer screening recommendations, as well as the various screening modalities available. The utility of PSA-based tests, serum and non-serum biomarkers, and multiparametric magnetic resonance imaging is discussed and evaluated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.